Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. Our non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, their patients and the healthcare system. Our first product, Bladder EpiCheck®, is CE-marked in Europe for primary and recurrent bladder and upper tract urinary cancer, and FDA 510(k) cleared in the U.S. for bladder cancer recurrence. It is commercially available in both regions. Our global team operates from San Diego, California in the US and Rehovot, Israel.
Company Details
- Employees
- 71
- Address
- Rehovot, Merkaz 76000, Il
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.nucleix.com
- HQ
- Rehovot, Merkaz
Nucleix Ltd. Questions
Nucleix Ltd.'s website is http://www.nucleix.com
Nucleix Ltd.'s LinkedIn profile is https://www.linkedin.com/company/nucleix
Nucleix Ltd. has
71 employees.
View email and phone details for 71
employees at Nucleix Ltd..
Nucleix Ltd.'s industry is
Biotechnology Research
Nucleix Ltd.'s top competitors are
Anima Biotech,
Biolojic Design, Ltd.,
Enzymit,
Cytoreason,
1e Therapeutics,
Immunai,
Evogene,
Nucleai,
Biomx (Nyse: Phge),
Memed.
Nucleix Ltd.'s categories are Biotechnology Research
